130 related articles for article (PubMed ID: 12042702)
1. The enigma of ectopic expression of FGFR3 in multiple myeloma: a critical initiating event or just a target for mutational activation during tumor progression.
Chesi M; Bergsagel PL; Kuehl WM
Curr Opin Hematol; 2002 Jul; 9(4):288-93. PubMed ID: 12042702
[TBL] [Abstract][Full Text] [Related]
2. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts.
Chesi M; Nardini E; Lim RS; Smith KD; Kuehl WM; Bergsagel PL
Blood; 1998 Nov; 92(9):3025-34. PubMed ID: 9787135
[TBL] [Abstract][Full Text] [Related]
3. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations.
Ronchetti D; Greco A; Compasso S; Colombo G; Dell'Era P; Otsuki T; Lombardi L; Neri A
Oncogene; 2001 Jun; 20(27):3553-62. PubMed ID: 11429702
[TBL] [Abstract][Full Text] [Related]
4. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma.
Chesi M; Brents LA; Ely SA; Bais C; Robbiani DF; Mesri EA; Kuehl WM; Bergsagel PL
Blood; 2001 Feb; 97(3):729-36. PubMed ID: 11157491
[TBL] [Abstract][Full Text] [Related]
5. Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis.
Plowright EE; Li Z; Bergsagel PL; Chesi M; Barber DL; Branch DR; Hawley RG; Stewart AK
Blood; 2000 Feb; 95(3):992-8. PubMed ID: 10648414
[TBL] [Abstract][Full Text] [Related]
6. Expression of fibroblast growth factor and FGF-receptor family genes in human myeloma cells, including lines possessing t(4;14)(q16.3;q32. 3) and FGFR3 translocation.
Otsuki T; Yamada O; Yata K; Sakaguchi H; Kurebayashi J; Nakazawa N; Taniwaki M; Yawata Y; Ueki A
Int J Oncol; 1999 Dec; 15(6):1205-12. PubMed ID: 10568829
[TBL] [Abstract][Full Text] [Related]
7. A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript.
Santra M; Zhan F; Tian E; Barlogie B; Shaughnessy J
Blood; 2003 Mar; 101(6):2374-6. PubMed ID: 12433679
[TBL] [Abstract][Full Text] [Related]
8. Novel mutation and RNA splice variant of fibroblast growth factor receptor 3 in multiple myeloma patients at diagnosis.
Soverini S; Terragna C; Testoni N; Ruggeri D; Tosi P; Zamagni E; Cellini C; Cavo M; Baccarani M; Tura S; Martinelli G
Haematologica; 2002 Oct; 87(10):1036-40. PubMed ID: 12368157
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma.
Zhu L; Somlo G; Zhou B; Shao J; Bedell V; Slovak ML; Liu X; Luo J; Yen Y
Mol Cancer Ther; 2005 May; 4(5):787-98. PubMed ID: 15897243
[TBL] [Abstract][Full Text] [Related]
10. Constitutively activated FGFR3 mutants signal through PLCgamma-dependent and -independent pathways for hematopoietic transformation.
Chen J; Williams IR; Lee BH; Duclos N; Huntly BJ; Donoghue DJ; Gilliland DG
Blood; 2005 Jul; 106(1):328-37. PubMed ID: 15784730
[TBL] [Abstract][Full Text] [Related]
11. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.
Trudel S; Li ZH; Wei E; Wiesmann M; Chang H; Chen C; Reece D; Heise C; Stewart AK
Blood; 2005 Apr; 105(7):2941-8. PubMed ID: 15598814
[TBL] [Abstract][Full Text] [Related]
12. Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14).
Intini D; Baldini L; Fabris S; Lombardi L; Ciceri G; Maiolo AT; Neri A
Br J Haematol; 2001 Aug; 114(2):362-4. PubMed ID: 11529856
[TBL] [Abstract][Full Text] [Related]
13. Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma.
Paterson JL; Li Z; Wen XY; Masih-Khan E; Chang H; Pollett JB; Trudel S; Stewart AK
Br J Haematol; 2004 Mar; 124(5):595-603. PubMed ID: 14871245
[TBL] [Abstract][Full Text] [Related]
14. The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells.
Li Z; Zhu YX; Plowright EE; Bergsagel PL; Chesi M; Patterson B; Hawley TS; Hawley RG; Stewart AK
Blood; 2001 Apr; 97(8):2413-9. PubMed ID: 11290605
[TBL] [Abstract][Full Text] [Related]
15. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3.
Chesi M; Nardini E; Brents LA; Schröck E; Ried T; Kuehl WM; Bergsagel PL
Nat Genet; 1997 Jul; 16(3):260-4. PubMed ID: 9207791
[TBL] [Abstract][Full Text] [Related]
16. Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses.
Fabris S; Agnelli L; Mattioli M; Baldini L; Ronchetti D; Morabito F; Verdelli D; Nobili L; Intini D; Callea V; Stelitano C; Lombardi L; Neri A
Genes Chromosomes Cancer; 2005 Feb; 42(2):117-27. PubMed ID: 15543617
[TBL] [Abstract][Full Text] [Related]
17. A molecular study of the t(4;14) in multiple myeloma.
Sibley K; Fenton JA; Dring AM; Ashcroft AJ; Rawstron AC; Morgan GJ
Br J Haematol; 2002 Aug; 118(2):514-20. PubMed ID: 12139740
[TBL] [Abstract][Full Text] [Related]
18. MMSET: role and therapeutic opportunities in multiple myeloma.
Xie Z; Chng WJ
Biomed Res Int; 2014; 2014():636514. PubMed ID: 25093175
[TBL] [Abstract][Full Text] [Related]
19. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression.
Keats JJ; Reiman T; Maxwell CA; Taylor BJ; Larratt LM; Mant MJ; Belch AR; Pilarski LM
Blood; 2003 Feb; 101(4):1520-9. PubMed ID: 12393535
[TBL] [Abstract][Full Text] [Related]
20. Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074.
Grand EK; Chase AJ; Heath C; Rahemtulla A; Cross NC
Leukemia; 2004 May; 18(5):962-6. PubMed ID: 15029211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]